These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 29227473)

  • 21. Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery.
    Reyes-Alcaraz A; Lee YN; Yun S; Hwang JI; Seong JY
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways.
    Liu Y; Yang Y; Ward R; An S; Guo XX; Li W; Xu TR
    Biochem J; 2015 Sep; 470(2):155-67. PubMed ID: 26348905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G protein-coupled receptors--recent advances.
    Latek D; Modzelewska A; Trzaskowski B; Palczewski K; Filipek S
    Acta Biochim Pol; 2012; 59(4):515-29. PubMed ID: 23251911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential.
    Seyedabadi M; Ghahremani MH; Albert PR
    Pharmacol Ther; 2019 Aug; 200():148-178. PubMed ID: 31075355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of Homology Modeling Assisted Molecular Docking in G-protein Coupled Receptors.
    Bhunia SS; Saxena AK
    Curr Top Med Chem; 2021; 21(4):269-294. PubMed ID: 32901584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis of β-arrestin coupling to formoterol-bound β
    Lee Y; Warne T; Nehmé R; Pandey S; Dwivedi-Agnihotri H; Chaturvedi M; Edwards PC; García-Nafría J; Leslie AGW; Shukla AK; Tate CG
    Nature; 2020 Jul; 583(7818):862-866. PubMed ID: 32555462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of β-arrestin-biased β
    Woo AY; Ge XY; Pan L; Xing G; Mo YM; Xing RJ; Li XR; Zhang YY; Wainer IW; Cheng MS; Xiao RP
    Acta Pharmacol Sin; 2019 Aug; 40(8):1095-1105. PubMed ID: 30643208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translating in vitro ligand bias into in vivo efficacy.
    Luttrell LM; Maudsley S; Gesty-Palmer D
    Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
    Bhattacharya S; Hall SE; Vaidehi N
    J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Template selection and refinement considerations for modelling aminergic GPCR-ligand complexes.
    Urmi KF; Finch AM; Griffith R
    J Mol Graph Model; 2017 Sep; 76():488-503. PubMed ID: 28818718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?
    Michino M; Beuming T; Donthamsetti P; Newman AH; Javitch JA; Shi L
    Pharmacol Rev; 2015; 67(1):198-213. PubMed ID: 25527701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular insights into the biased signaling mechanism of the μ-opioid receptor.
    Cong X; Maurel D; Déméné H; Vasiliauskaité-Brooks I; Hagelberger J; Peysson F; Saint-Paul J; Golebiowski J; Granier S; Sounier R
    Mol Cell; 2021 Oct; 81(20):4165-4175.e6. PubMed ID: 34433090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery.
    Correll CC; McKittrick BA
    J Med Chem; 2014 Aug; 57(16):6887-96. PubMed ID: 24697360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-mass MALDI-MS unravels ligand-mediated G protein-coupling selectivity to GPCRs.
    Wu N; Olechwier AM; Brunner C; Edwards PC; Tsai CJ; Tate CG; Schertler GFX; Schneider G; Deupi X; Zenobi R; Ma P
    Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPCR-IPL score: multilevel featurization of GPCR-ligand interaction patterns and prediction of ligand functions from selectivity to biased activation.
    Kumar S; Teli MK; Kim MH
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38517694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterizing Rhodopsin-Arrestin Interactions with the Fragment Molecular Orbital (FMO) Method.
    Heifetz A; Townsend-Nicholson A
    Methods Mol Biol; 2020; 2114():177-186. PubMed ID: 32016894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation-induced conformation of β
    Shiraishi Y; Natsume M; Kofuku Y; Imai S; Nakata K; Mizukoshi T; Ueda T; Iwaï H; Shimada I
    Nat Commun; 2018 Jan; 9(1):194. PubMed ID: 29335412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of structural dynamics in GPCR-mediated signaling.
    Hilger D
    FEBS J; 2021 Apr; 288(8):2461-2489. PubMed ID: 33871923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and Opportunities in Drug Discovery of Biased Ligands.
    Rodríguez-Espigares I; Kaczor AA; Stepniewski TM; Selent J
    Methods Mol Biol; 2018; 1705():321-334. PubMed ID: 29188569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.
    Zhu Y; Yuan Y; Xiao X; Zhang L; Guo Y; Pu X
    J Mol Model; 2014 Nov; 20(11):2491. PubMed ID: 25342155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.